January 17, 2008

Novo Halts Inhaled Insulin, Citing Lack of Benefit

Jan. 14 (Bloomberg) -- Novo Nordisk A/S discontinued its experimental AERx inhaler and took a charge of 1.3 billion Danish kroner ($260 million) in 2007, saying the product offered little clinical benefit.

http://www.bloomberg.com/apps/news?pid=20601087&sid=azV7Nv7fLQNg&refer=home